Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2020-09-30 Capital/Financing Update
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release dated September 30, 2020, announcing that HLS Therapeutics has acquired a portfolio of royalty interests. It details the transaction highlights, financial terms, and strategic rationale behind the acquisition. The content focuses on the acquisition event, financial implications, and future expectations related to the portfolio. There are no comprehensive financial statements, quarterly or annual results, or detailed management discussion of financial performance. The document is not a full financial report but rather an announcement of a capital transaction and financing update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 12,000 characters, indicating it is a full announcement rather than a brief note or regulatory filing. Hence, the classification is CAP with high confidence.
2020-09-30 English
News release - English.pdf
Legal Proceedings Report Classification · 90% confidence The document is a press release from HLS Therapeutics commenting on a U.S. Court of Appeals decision related to patent litigation involving Amarin's Vascepa product. It discusses the impact of the U.S. ruling on the Canadian market and provides forward-looking statements about the company's business outlook. There are no financial statements, detailed financial data, or comprehensive report content. The document is an announcement regarding a legal and business update rather than a full legal proceedings report or financial report. It is not a detailed legal proceeding report (LTR) because it is a general comment on litigation outcome rather than a detailed legal filing or update. It is also not a regulatory filing or report publication announcement. Given the nature of the content as a press release commenting on litigation and business impact, the best fitting category is Legal Proceedings Report (LTR).
2020-09-03 English
News release - English.pdf
Regulatory Filings
2020-08-31 English
News release - English.pdf
Regulatory Filings
2020-08-07 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing the Q2 2020 financial results of HLS Therapeutics. It contains detailed financial data for the quarter and year-to-date periods, including revenue, adjusted EBITDA, net loss, cash flow, and debt information. It also announces a CEO succession and a dividend declaration. The presence of comprehensive financial results and analysis for a quarterly period indicates this is a quarterly financial report. The document also mentions a conference call to discuss these results, which is typical for earnings releases or interim reports. Given the detailed financial data and the quarterly period focus, this document fits the definition of an Interim / Quarterly Report (IR). It is not merely an earnings release (ER) because it contains substantive financial data and analysis, not just key highlights. It is not a report publication announcement (RPA) because the full report content is included, not just a notice of availability. Therefore, the correct classification is IR with high confidence. Q2 2020
2020-08-06 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of HLS Therapeutics Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2020. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3358 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-08-06 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.